# Prompts to LLM:

### Instructions ###

You are assisting a team of expert clinical pharmacists, drug interaction pharmacology researchers, and persons who edit drug interaction knowledge compendia. You help synthesize evidence about possible interactions between prescription drugs and natural products (botanical or herbal) based on the most recent and relevant information. Ground your response in factual data from your pre-train set or any context provided by the user, explicitly referencing or quoting authoritative sources when possible. In your response, think carefully and be specific about the source of the information used in each answer, and avoid citing sources if the information is not a direct citation from that source. Always explain your reasoning. Make it explicit when you base your reasoning on pharmacological inference rather than a direct citation from a textual source. Focus on factuality since you must evaluate your answer in the end. Structure your response using the following nine-item template: 

Item 1: A list of each potential mechanism, showing each step in your thinking and providing evidence to support each step involved.  

Item 2: A description of the natural product mentioned in the query. Please include a list of known names to refer to the product and note how it is prepared or consumed.  

Item 3: A summary of the pharmacokinetic properties of the natural product mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and the average amount of bioactive compounds in the products. 

Item 4: A brief description of the drug mentioned in the query. Include a list of known names used to refer to the drug. 

Item 5: A summary of the pharmacokinetic properties of the drug mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and standardized dosage of the drug's active ingredient.

Item 6: A summarized description of the adverse event mentioned in the query. List known potential causes and if the mentioned natural product or drug is associated with the adverse event. Include all available details regarding the average onset time of the adverse event. Include all available information regarding the likelihood of overlapping effects of the adverse event. Include all available details regarding the potential additive nature of the side effects involved in the adverse event. 

Item 7: A list and description of any mention of clinical importance for the interaction, including the frequency of the mentions. 

Item 8: A list of other drugs with similar pharmacodynamic and pharmacokinetic properties to the drug in the query that could interact with the natural product mentioned. 

Item 9: A list of other natural products with similar pharmacodynamic and pharmacokinetic properties to the natural product in the query that could interact with the drug mentioned.

Finally, classify how accurate your synthesis was. Rate your confidence in your answers on a scale of 1-5, 1 being very low and 5 being very high.



### Context ###


Include relevant items from the following information in your synthesis:
The Natural Product gingerol directly negatively regulates activity of the Enzyme or Transporter ATP-dependent translocase ABCB1 (human). The Drug tacrolimus (anhydrous) transports the Enzyme or Transporter ATP-dependent translocase ABCB1 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:zingiber_officinale Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_10136 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002449 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08183 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002020 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

-----

The Natural Product 1,8-cineole interacts with the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) is substrate of the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:zingiber_officinale Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_27961 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002434 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/DIDEO_00000041 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

-----

The Natural Product 1,8-cineole interacts with the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) is substrate of the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_27961 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002434 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/DIDEO_00000041 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

-----

Ginger Unnamed: 1 Unnamed: 2 Zingiber officinale Roscoe (Zingiberaceae) Synonym(s) and related species Gan Jiang Zingiber Monograph Interpretation Citation Anticoaguants Evidence from pharmacological studies suggests that ginger does not increase the anticoagulant effect of warfarin, neither does it alter coagulation or platelet aggregation on its own. However, two cases reports describe markedly raised INRs with phenprocoumon and warfarin, which were associated with eating dried ginger and drinking ginger tea. A prospective, longitudinal study also reports of an increased risk of self-reported bleeding events in patients taking warfarin and ginger. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, LcLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425-32. Kruth P, Brosi E, Fux R, Morike K, Gleiter CH. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother (2004) 38, 257-60. Lesho EP, Saullo L, Udvari-Nagy S. A 76-year-old woman with erratic anticoagulation. Cleve Clin J Med (2004) 71, 651-6. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy (2007) 27, 1237-47. Argento A, Tiraferri E, Marzaloni M. Anticoagulanti orali e piante medicinali. Una interazione emergente. Ann Ital Med Int (2000) 15, 139-43. Braun L. Herb-drug interaction guide. Aust Fam Physician (2001) 30, 473-6. Vacs LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478-82. Young H-Y, Liao J-C, Chang Y-S, Luo Y-L, Lu M-C, Peng W-H. Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volenteers. Am J Chin Med (2006) 34, 545-51. Caffeine For mention that sho-saiko-to (of which ginger is one of 7 constituents) onoy slightly reduced the metabolism of caffeine in one study, see Bupleurum + Caffeine, page 99. Carbamazepine For mention that saiko-ka-ryukotsu-borei-to and sho-saiko-to (of which ginger is one of a number of constituents) did not affect the pharmacokinetics of carbamazepine in animal studies, see Bupleurum + Carbamazepine, page 99. Food Not interactions found. Ginger is extensively used as a food ingredient. Herbal medicines No interactions found. Isoiazid For details of an animal study to investigate a possible interaction between isoniazid and Trikatu, an Ayurvedic medicine containing ginger, black pepper and long pepper, see Pepper + Isoniazid, page 375. Nifedipine A small study found that antiplatelet effects for ginger were synergistic with those nifedipine, but any effect needs confirmation. Young H-Y, Laio J-C, Chang Y-S, Luo Y-L, Lu M-C, Peng W-H. Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volunteers. Am J Chin Med (2006) 34, 545-51. Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478-82. NSAIDs For details of an animal study to investigate a possibe interaction between diclofenac and Trikatu, an Ayurvedic medicine containing ginger, black pepper and long pepper, see Pepper + NSAIDs page 376

-----

The Natural Product curcumin interacts with the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) molecularly interacts with the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event peripheral neuropathy. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_3962 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002434 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002436 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0005244

-----

The Natural Product curcumin directly negatively regulates quantity of the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) is substrate of the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_3962 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0011010 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/DIDEO_00000041 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

-----

The Natural Product gingerol directly negatively regulates activity of the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) is substrate of the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:zingiber_officinale Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_10136 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002449 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/DIDEO_00000041 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

### Query ###

What are the potential mechanisms that cause an interaction between Ginger products and Tacrolimus that may cause Nephrotoxicity?

-------

# Response from LLM:

 Item 1: Potential mechanisms for an interaction between Ginger products and Tacrolimus that may cause nephrotoxicity:

1. Inhibition of the transporter ABCB1 (ATP-dependent translocase) by Gingerol, a constituent of Ginger, could potentially reduce the renal excretion of Tacrolimus, leading to increased Tacrolimus concentrations in the body. This could potentially increase the risk of nephrotoxicity.

2. Induction of the enzyme cytochrome P450 3A4 (CYP3A4) by Gingerol, Curcumin, and 1,8-cineole (constituents of Ginger) could potentially increase the metabolism of Tacrolimus, leading to decreased Tacrolimus concentrations in the body. This could potentially reduce the efficacy of Tacrolimus and increase the risk of nephrotoxicity due to higher Tacrolimus concentrations being required to achieve therapeutic effects.

Item 2: Ginger (Zingiber officinale Roscoe, Zingiberaceae) is a Natural Product. It is commonly consumed as a spice, in the form of fresh, dried, or powdered ginger root.

Item 3: The pharmacokinetic properties of Ginger are not well-defined due to its complex composition and variability in preparation. However, Gingerol is the main bioactive compound in Ginger, and it is known to have low oral bioavailability due to extensive metabolism and poor absorption.

Item 4: Tacrolimus (anhydrous) is a Drug used to prevent organ rejection in transplant patients. It is available under various brand names, such as Prograf and Astagraf XL.

Item 5: Tacrolimus has a long half-life (50-72 hours) and is primarily metabolized by CYP3A4 in the liver. It is administered orally and has a high bioavailability (60-80%).

Item 6: Nephrotoxicity is a potential adverse event associated with Tacrolimus use, characterized by kidney damage, including acute kidney failure. The exact mechanism of Tacrolimus-induced nephrotoxicity is not fully understood, but it is thought to involve direct tubular injury, glomerular injury, and hemodynamic changes.

Item 7: Clinical importance for the interaction between Ginger and Tacrolimus in causing nephrotoxicity is not well-established, but there is evidence suggesting that Ginger may affect the pharmacokinetics of Tacrolimus, potentially increasing the risk of nephrotoxicity.

Item 8: Other drugs with similar pharmacodynamic and pharmacokinetic properties to Tacrolimus that could interact with Ginger include Cyclosporine, Sirolimus, and Everolimus, all of which are also immunosuppressants and are metabolized by CYP3A4.

Item 9: Other Natural Products with similar pharmacodynamic and pharmacokinetic properties to Ginger that could interact with Tacrolimus include Turmeric (Curcuma longa), which contains Curcumin, and Essential oils containing 1,8-cineole, such as Eucalyptus oil. Both Curcumin and 1,8-cineole are known to induce CYP3A4.

Classification: 4 (Moderate confidence) - While there is evidence suggesting that Ginger may affect the pharmacokinetics of Tacrolimus, the clinical importance and specific mechanisms of this interaction are not fully understood.